PEDIATRIC LATE OUTCOMES (AIDS CLINICAL TRIAL GROUP # 219)

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 主要目标是： 1.描述目前或以前在儿科ACTG方案中登记的感染人类免疫缺陷病毒(HIV)的婴儿、儿童和青少年随着时间的推移在生长、神经和神经心理功能、器官系统毒性、癌症发展以及免疫学和病毒学参数方面的晚期结果，并评估这些儿童接受包括疫苗在内的治疗的潜在晚期影响。 2.确定参加ACTG新生儿/早期治疗方案的艾滋病毒状况不确定的婴儿，以及在怀孕期间登记参加围产期或抗逆转录病毒/免疫调节剂治疗的艾滋病毒感染妇女所生的未感染婴儿，是否表现出在子宫和/或新生儿期接受抗逆转录病毒治疗的任何短期或长期的临床、神经、神经心理或器官系统延迟效应。这将包括对疫苗疗法的后期效果(无论是积极的还是消极的)进行评估。 3.跟踪在ACTG方案中登记的感染艾滋病毒的婴儿、儿童和青少年的总体存活率、发病率和生活质量。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary objectives are: 1. To describe late outcomes over time in growth, neurologic and neuropsychologic function, organ system toxicity, development of cancer, and immunologic and virologic parameters in human immunodeficiency virus (HIV) infected infants, children, and adolescents, currently or previously enrolled in pediatric ACTG protocols, and to evaluate the potential late effects of therapies, including vaccines, received by these children. 2. To determine if infants with indeterminate HIV status who enroll in ACTG neonatal/early infancy protocols involving antiretrovirals, vaccines, or immunotherapy, and uninfected infants born to HIV-infected women who were enrolled in perinatal or antiretroviral/immunomodulator therapy ACTG protocols while pregnant demonstrate any short or long term clinical, neurologic, neuropsychologic, or organ system late effects of antiretroviral therapy received in utero and/or in the newborn period. This will include evaluation of late effects (either positive or negative) of vaccine therapies. 3. To follow overall survival, morbidity, and quality of life in successive cohorts of HIV infected infants, children, and adolescents enrolled in ACTG protocols.